What do we know about the reduction of Pt(IV) pro-drugs?

Ezequiel Wexselblatt, Dan Gibson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

312 Scopus citations

Abstract

Platinum(IV) pro-drugs are an important class of molecules that might improve the pharmacological properties of the platinum(II) anticancer agents that are currently used in the clinic. Their axial ligands that are detached during cellular activation by reductive elimination can be used to confer favorable pharmacological properties to the complexes allowing for potentially lower toxicity and improved efficacy. This manuscript describes the various approaches taken to design and prepare Pt(IV) complexes that will be effective anticancer agents. We review the working hypotheses guiding the researchers in the field while pointing out some more recent results that contradict some of the accepted paradigms in the hope of triggering some rethinking of the existing working hypotheses.

Original languageEnglish
Pages (from-to)220-229
Number of pages10
JournalJournal of Inorganic Biochemistry
Volume117
DOIs
StatePublished - Dec 2012

Fingerprint

Dive into the research topics of 'What do we know about the reduction of Pt(IV) pro-drugs?'. Together they form a unique fingerprint.

Cite this